Revisiting the Role of Genetic Testing in Patients at Risk for Late-Onset Alzheimer’s Disease: How Will the Latest Evidence and Evolving Management Paradigm Impact Treatment Decisions for Your Patients?

Chair, Robert C. Green, MD, MPH, Liana G. Apostolova, MS, MD, FAAN, and Stephen P. Salloway, MD, MS, discuss Alzheimer’s disease in this CME/NCPD/CPE/ASWB-ACE/IPCE activity titled “Revisiting the Role of Genetic Testing in Patients at Risk for Late-Onset Alzheimer’s Disease: How Will the Latest Evidence and Evolving Management Paradigm Impact Treatment Decisions for Your Patients?” For the full presentation, downloadable Practice Aids, and complete CME/NCPD/CPE/ASWB-ACE/IPCE information, and to apply for credit, please visit us at https://bit.ly/3ZwBKIA. CME/NCPD/CPE/ASWB-ACE/IPCE credit will be available until April 15, 2024.